Phase II Trial of Cisplatin, Etoposide and Paclitaxel (Taxol®) With G-CSF in Untreated Patients with Extensive Small Cell Lung Cancer

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group 1,2

K Kelly;PA Bunn;L Lovato;J Crowley;RB Livingston;DR Gandara Clinical Cancer Research 7:2325-2329

Final results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung (SCLC).

K Kelly;PA Bunn;L Lovato;J Crowley;RB Livingston;DR Gandara Proc of the American Society of Clinical Oncology 19:492a(#1923)

A phase II study of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: a Southwest Oncology Group trial.

K Kelly;PA Bunn;L Lovato;J Crowley;RB Livingston;DR Gandara Lung Cancer 29(Suppl.2):8(#20)

Preliminary toxicity results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung cancer (SCLC).

PA Bunn;K Kelly;J Crowley;RB Livingston;DR Gandara Proc of the American Society of Clinical Oncology 18:468a(#1807)